PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Strontium”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,279 records · Page 71Linked to original sources
PubMed1981

[Biorhythm changes in DNA synthesis in hepatocytes exposed to organophosphates and strontium-89].

The authors irradiated albino rats with I microc/gr strontium89 with previously modelled liver injury by FOS (Agria 1050). A temporary inhibition of the methodical activity was established as well as aberrant mitoses and strongly manifested polyploidity of the hepatic cells. Those phenomena faded quickly (within 8 days), with the exception of polyploidity, which as a sign of physiological regeneration the authors admit to be adaptive reaction directed to the restoration of the functional level of the liver on account of the hepatocytes preserved. Prior to the onset of tissue regeneration, the cellular one should be terminated, due to which, the mytotic activity was highly inhibited on the 3rd day of the irradiation, the DNA-synthesis cycle being lengthened and mainly on account of tgi, i.e. during the reparative biosynthesis the cell is incapable/of developing in the mitotic phase. After the presynthetic period is over the hepatocytes rapidly overcome the inhibition, tgi is considerably shortened and from presynthesis they almost immediately enter the period of mitosis. That requires an additional protein synthesis, manifested by the changes in serum protein. S and G1 proved to be most sensitive to DNA-synthesis blocking. The presynthetic period is essentially lengthened due to lesions of the cellular structures, synthesizing substances, necessary for entering S - i.e. the hepatocytes pass T, equal to the inhibition between G1 and S, its duration being proportional to the degree of the lesion of the organ.

Animals↗
PubMed1997

Autopsy of a cadaver containing strontium-89-chloride.

An autopsy was performed on a patient who died after receiving 89Sr-chloride for treatment of bone pain from metastatic prostate carcinoma. Coordination between nuclear medicine physicians, radiation safety division personnel and pathologists resulted in minimal radiation exposure and the acquisition of dosimetry data.

Aged↗
PubMed1997

Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma.

UNLABELLED: The urinary production of pyridinium collagen cross-links, pyridinoline (PYD) and deoxypyridinoline (DPD), has been correlated to increased bone resorption in patients with neoplasms. This study investigated the production of these compounds in patients with metastatic prostate carcinoma who received palliative treatment that did and did not include 89Sr-chloride therapy. METHODS: Urinary production of PYD and DPD was measured by high-performance liquid chromatography and natural flucrescence detection methods. The urine from several age-matched groups of patients was examined for these compounds including healthy controls (n = 20), patients with early-stage (Stage A-B) prostate carcinoma (n = 8), patients with metastatic prostate carcinoma treated with conventional analgesic and radiotherapeutic palliation (n = 20), patients with metastatic disease who underwent 89Sr-chloride therapy (n = 20) and patients with mild Paget's disease (n = 5). Patients were also monitored for urinary PYD and DPD production for a 6-mo interval after a palliative intervention. RESULTS: Elevated PYD and DPD (p < 0.05) concentrations were measured in patients with metastatic and nonmetastatic prostate cancer and Paget's disease. The urinary production of these compounds remained unchanged for 6 mo after 89Sr-chloride therapy for symptomatic osseous metastases. However, the patients who did not undergo 89Sr-chloride therapy exhibited a two-fold increase in PYD and a four-fold increase in DPD above controls during the interval. CONCLUSION: PYD and DPD are sensitive and specific bone resorption markers which demonstrate a slowing of bone resorption after palliative 89Sr-chloride therapy in patients with bone metastases.

Aged↗